lenalidomide subcutaneous prolonged-release (NEX-20A) / Nanexa AB - LARVOL DELTA

To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: Nanexa AB | Initiation date: May 2023 ➔ Nov 2022

Trial initiation date • Hematological Malignancies • Multiple Myeloma • Oncology

To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: Nanexa AB | Recruiting ➔ Completed | Initiation date: Nov 2022 ➔ May 2023 | Trial primary completion date: Jun 2023 ➔ Sep 2023

Trial completion • Trial initiation date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Nanexa has completed the planned recruitment to the Phase 1 study of NEX-20 (Market Screener) - "Nanexa AB today announced that the recruitment and dosing has been completed in the NEX-20 Phase 1 study. Since December last year, healthy volunteers have been administered single doses in three sequential escalating dose groups. Data on the pharmacokinetic profile, safety and tolerability is now being collected for the last dose group, and results are expected to be presented after the summer."

P1 data • Trial status • Oncology

To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Nanexa AB | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology